SSGJ-705
- Generic Name
- SSGJ-705
A Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of SSGJ-705 Monotherapy in Patients with Advanced Malignant Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced, Recurrent or Metastatic Malignancies
- Interventions
- First Posted Date
- 2024-04-30
- Last Posted Date
- 2024-10-18
- Target Recruit Count
- 180
- Registration Number
- NCT06390774
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Shandong First Medical University, Jinan, Shandong, China
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Potential Anti-tumor Effects of SSGJ-705 in Patients With Advanced or Metastatic HER2-expressing Solid Tumors
- First Posted Date
- 2021-12-06
- Last Posted Date
- 2021-12-06
- Target Recruit Count
- 162
- Registration Number
- NCT05145179
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath